PACAP-38 is a chemorepellent and an agonist for the lysozyme receptor in Tetrahymena thermophila

被引:0
|
作者
S. R. Mace
J. G. Dean
J. R. Murphy
J. L. Rhodes
H. G. Kuruvilla
机构
[1] Cedarville College,
[2] Department of Science and Mathematics,undefined
[3] PO Box 601,undefined
[4] Cedarville,undefined
[5] OH 45314,undefined
[6] USA e-mail: kuruvilh@cedarville.edu Tel.: +1-937-766-7606; Fax: +1-937-766-7631,undefined
来源
Journal of Comparative Physiology A | 2000年 / 186卷
关键词
Key words Chemorepellent; PACAP-38; Tetrahymena; Chemosensory transduction; Behavioral adaptation;
D O I
暂无
中图分类号
学科分类号
摘要
Pituitary adenylate cyclase activating peptide (PACAP-38) is a peptide hormone which functions in many mammalian systems, including the nervous and digestive systems. Using in vivo behavioral studies, we have found that this hormone functions as a chemorepellent in Tetrahymena thermophila with an EC50 of 10 nM. Cells previously adapted to PACAP-38 were found to be adapted to lysozyme, and vice versa. Furthermore, the in vivo behavioral activity of PACAP-38 was blocked by addition of the anti-lysozyme receptor antibody, 5545. Chemorepellent activity of PACAP-38 was also inhibited by the addition of neomycin sulfate (inhibition constant Ki=0.080 μmol · l−1), a competitive inhibitor of lysozyme binding to its receptor. PACAP-38 is a more potent and specific agonist for the lysozyme receptor than either intact lysozyme or CB2, a 24-amino acid fragment of lysozyme.
引用
收藏
页码:39 / 43
页数:4
相关论文
共 50 条
  • [41] CGRP and PACAP-38 play an important role in diagnosing pediatric migraine
    Junhui Liu
    Guan Wang
    Yuan Dan
    Xinjie Liu
    The Journal of Headache and Pain, 2022, 23
  • [42] CGRP and PACAP-38 play an important role in diagnosing pediatric migraine
    Liu, Junhui
    Wang, Guan
    Dan, Yuan
    Liu, Xinjie
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [43] BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons
    Frechilla, D
    García-Osta, A
    Palacios, S
    Cenarruzabeitia, E
    Del Río, J
    NEUROREPORT, 2001, 12 (05) : 919 - 923
  • [44] Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention
    Pellesi, Lanfranco
    Ashina, Messoud
    Martelletti, Paolo
    EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (01) : 57 - 64
  • [45] Release of PACAP-38 in episodic cluster headache patients – an exploratory study
    Bernadett Tuka
    Nikoletta Szabó
    Eszter Tóth
    Zsigmond Tamás Kincses
    Árpád Párdutz
    Délia Szok
    Tamás Körtési
    Teréz Bagoly
    Zsuzsanna Helyes
    Lars Edvinsson
    László Vécsei
    János Tajti
    The Journal of Headache and Pain, 2016, 17
  • [46] COMPARISON OF RESPONSES TO PACAP-38, PACAP-27, AND VIP IN THE PULMONARY AND SYSTEMIC VASCULAR BEDS OF THE CAT
    MCMAHON, TJ
    SANTIAGO, JA
    DEWITT, BJ
    CHENG, DY
    GARRISON, EA
    DENT, E
    VENTURA, V
    PURNELL, W
    KADOWITZ, PJ
    FASEB JOURNAL, 1994, 8 (04): : A42 - A42
  • [47] PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients
    Szabo, Dora
    Sarszegi, Zsolt
    Polgar, Beata
    Saghy, Eva
    Reglodi, Dora
    Toth, Tunde
    Onodi, Zsofia
    Leszek, Przemyslaw
    Varga, Zoltan V.
    Helyes, Zsuzsanna
    Kemeny, Agnes
    Ferdinandy, Peter
    Tamas, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [48] The Effect of VIP and PACAP-38 on CGRP Release in Dura Mater, TG and TNC
    Baun, M.
    Amrutkar, D., V
    Olesen, J.
    Jansen-Olesen, I
    HEADACHE, 2012, 52 (05): : 906 - 906
  • [49] Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38
    Baun, Michael
    Pedersen, Martin Holst Friborg
    Olesen, Jes
    Jansen-Olesen, Inger
    CEPHALALGIA, 2012, 32 (04) : 337 - 345
  • [50] Presence of Endogenous PACAP-38 Ameliorated Intestinal Cold Preservation Tissue Injury
    Ferencz, Andrea
    Weber, Gyorgy
    Helyes, Zsuzsanna
    Hashimoto, Hitoshi
    Baba, Akemichi
    Reglodi, Dora
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2010, 42 (03) : 428 - 434